Literature DB >> 3153710

Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam.

M Mattila1, T Seppala, M J Mattila.   

Abstract

Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, tapping, heterophoria) were done at baseline, and post treatment. YOH shifted the healthy subjects' mood towards feeling panicked, elevated systolic blood pressure and plasma prolactin concentrations, reduced digit symbol substitution, and induced drowsiness and passiveness. Caffeine (CAF) 10 mg/kg raised plasma cortisol and rendered the subjects slightly panicked. Muzziness, clumsiness, tremor, chills and nausea were common after both YOH and CAF. Diazepam (DZ) 0.3 mg/kg given at 60 min antagonized some effects of CAF but failed to antagonize YOH. Clonidine (CLO) 100 micrograms counteracted YOH effects on blood pressure but less the subjective and hormonal effects. CLO 200 micrograms partly antagonized the pressor, sedative but not the hormonal responses of YOH. DZ counteracted YOH effects on plasma cortisol on panic but not on other subjective measures or plasma prolactin. Since CLO did not abolish YOH-induced prolactin increase, it is suggested that these effects of YOH are mediated not only via adrenergic alpha 2-receptors; other mechanisms made important contributions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3153710     DOI: 10.1097/00004850-198807000-00003

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  9 in total

1.  Pharmacology of saccadic eye movements in man. 2. Effects of the alpha 2-adrenoceptor ligands idazoxan and clonidine.

Authors:  P Glue; E White; S Wilson; D M Ball; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.

Authors:  Mark K Greenwald; Leslie H Lundahl; Caren L Steinmiller
Journal:  Psychopharmacology (Berl)       Date:  2012-11-17       Impact factor: 4.530

3.  A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

Authors:  W S Redfern; A Williams
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

4.  Yohimbine premedication and 35% CO2 vulnerability in healthy volunteers.

Authors:  H Pols; E Griez; K Verburg; D van der Werf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

5.  Alterations in ethanol seeking and self-administration following yohimbine in selectively bred alcohol-preferring (P) and high alcohol drinking (HAD-2) rats.

Authors:  Megan L Bertholomey; Terril L Verplaetse; Cristine L Czachowski
Journal:  Behav Brain Res       Date:  2012-10-26       Impact factor: 3.332

6.  Gonadal hormones affect alcohol drinking, but not cue+yohimbine-induced alcohol seeking, in male and female rats.

Authors:  Megan L Bertholomey; Mary M Torregrossa
Journal:  Physiol Behav       Date:  2017-10-26

7.  Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers.

Authors:  S Karhuvaara; A Kallio; M Scheinin; M Anttila; J S Salonen; H Scheinin
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 8.  Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.

Authors:  Mark K Greenwald
Journal:  Neurobiol Stress       Date:  2018-08-11

9.  Differences in trait impulsivity do not bias the response to pharmacological drug challenge in the rat five-choice serial reaction time task.

Authors:  Rebecca L Barlow; Jeffrey W Dalley; Anton Pekcec
Journal:  Psychopharmacology (Berl)       Date:  2018-01-26       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.